Free Trial
NASDAQ:MNPR

Monopar Therapeutics Q4 2024 Earnings Report

Monopar Therapeutics logo
$36.31 +1.50 (+4.31%)
As of 02:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Monopar Therapeutics EPS Results

Actual EPS
-$2.23
Consensus EPS
-$0.36
Beat/Miss
Missed by -$1.87
One Year Ago EPS
N/A

Monopar Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Monopar Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 31, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Monopar Therapeutics' Q3 2025 earnings is scheduled for Friday, November 14, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Monopar Therapeutics Earnings Headlines

Monopar Therapeutics (NASDAQ:MNPR) Now Covered by HC Wainwright
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.tc pixel
FY2025 EPS Estimate for Monopar Therapeutics Cut by Analyst
See More Monopar Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Monopar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monopar Therapeutics and other key companies, straight to your email.

About Monopar Therapeutics

Monopar Therapeutics (NASDAQ:MNPR), a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

View Monopar Therapeutics Profile

More Earnings Resources from MarketBeat